



For enhanced screening of
Cervical Cancer,

Dr. Lal PathLabs presents the new
Oncogenic HPV E6/E7 mRNA test
which improves the specificity of the
detection process for high grade lesion.

 *Dr Lal PathLabs*

National Customer Care: (011-3000-5000)

Oncogenic HPV E6/E7 mRNA Introduction :

HPV E6/E7 mRNA test is a cell based assay which uses a novel in situ-hybridization technique. It is based on the fact that Oncogenic genotypes of HPV can express E6 and E7 mRNA following integration of HPV into genomic DNA; a process that causes cellular transformation and progression to Cervical cancer.

Oncogenic HPV E6/E7 mRNA Utilities

- E6/E7 mRNA over expression appears to be a good prognostic marker to manage HR-HPV DNA positive women with negative Colposcopy or Histology, particularly in order to decrease follow up intensity in those who are tested negative.¹
- Higher specificity and PPV of HPV E6/E7 mRNA testing are valuable in predicting insignificant HPV DNA infection amongst the cases with borderline cytological findings.²
- Helps in avoiding aggressive procedures (biopsies and over referral of transient HPV infections).²
- Lowers patient's anxiety and follow up period.²

Human Papilloma Virus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.³

- mRNA testing efficacy is helpful in predicting histological diagnosis in case of HPV 16 and/or 18 DNA detection.
- mRNA sensitivity was 81.3% and 84.1%, respectively. Specificity was 52.2%, and 80.0%, respectively.
- Negative Predictive Value (NPV) was 88.9% in undetermined or low-grade squamous lesions.
- Positive Predictive Value (PPV) was 97.4% in high-grade squamous lesions.
- mRNA reduced need for colposcopies by 44.3% in undetermined or low-grade squamous lesions.

Cervical Cancer Screening Guidelines

21-29 yrs.	30-65 yrs.
Pap test every 3 years	Pap test and HPV test every 5 years

*American Cancer Society, ACOG July, 2014

Test Details

Test Name	Method	Specimen	Report
Oncogenic HPV E6/E7 mRNA	Flow Cytometry	Cervical swab/cells in special container with medium available from LPL. Ship refrigerated.	Sample by 9:00 am on Tues/Thurs/Sat; Report on Wed/Fri/Monday evening

Also available

- Cytology Pap smear, Genital, Female and Liquid Based.
- Cervical Screening
*Cervical PAP Smear, Genital, Female (Liquid Based)*Human Papilloma Virus (HPV) Detection and Genotyping, PCR, Qualitative.
- BRCA1 & BRCA2 Mutation Screening
- BRCA1 & BRCA2 Mutation Comprehensive Panel
- ROMA (Rise Of Malignancy Algorithm)
- HE4 ; Human Epididymis Protein 4
- Ovarian Cancer Panel (CA 125 * Inhibin B)

References

1. J Med Virol. 2013 Jun;85(6):1063-8
2. Plos one 2013;8 (2):e57600
3. J Med Virol. 2015 sep;87 (9): 1578-86